MedTrace Logo

Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis

NCT02344823 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-09-25

No results posted yet for this study

Summary

The investigators want to analyze the effect of Vardenafil on Erectile Dysfunstion and portal hemodynamics in patients with liver cirrhosis.

Conditions

Interventions

DRUG

Vardenafil

per oral intake of 10mg Vardenafil once daily

PROCEDURE

HVPG (Hepatic venous pressure measurement) baseline

HVPG measurement day 1

PROCEDURE

HVPG (Hepatic venous pressure measurement) day 7

HVPG measurement day 7

BEHAVIORAL

IIEF 5 (International Index of Erectile Function) questionaire baseline

IIEF 5 questionaire to define level of erectile dysfunction at baseline

BEHAVIORAL

IIEF 5 (International Index of Erectile Function) questionnaire at study phase end

IIEF 5 questionaire to define level of erectile dysfunction at end of study phase

DRUG

Placebo intake once daily

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Arnulf Ferlitsch, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02344823 on ClinicalTrials.gov